- •Table of Contents
- •Copyright
- •Contributors
- •How to Use this Study Guide
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •4: Outcomes Research
- •Questions
- •Answers
- •5: Core Principles of Perioperative Care
- •Questions
- •Answers
- •Questions
- •Answers
- •7: Principles of Urologic Endoscopy
- •Questions
- •Answers
- •8: Percutaneous Approaches to the Upper Urinary Tract Collecting System
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •12: Infections of the Urinary Tract
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •15: Sexually Transmitted Diseases
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •20: Principles of Tissue Engineering
- •Questions
- •Answers
- •Questions
- •Answers
- •22: Male Reproductive Physiology
- •Questions
- •Answers
- •Questions
- •Answers
- •24: Male Infertility
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •28: Priapism
- •Questions
- •Answers
- •Questions
- •Answers
- •30: Surgery for Erectile Dysfunction
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •34: Neoplasms of the Testis
- •Questions
- •Answers
- •35: Surgery of Testicular Tumors
- •Questions
- •Answers
- •36: Laparoscopic and Robotic-Assisted Retroperitoneal Lymphadenectomy for Testicular Tumors
- •Questions
- •Answers
- •37: Tumors of the Penis
- •Questions
- •Answers
- •38: Tumors of the Urethra
- •Questions
- •Answers
- •39: Inguinal Node Dissection
- •Questions
- •Answers
- •40: Surgery of the Penis and Urethra
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •47: Renal Transplantation
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •50: Upper Urinary Tract Trauma
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •53: Strategies for Nonmedical Management of Upper Urinary Tract Calculi
- •Questions
- •Answers
- •54: Surgical Management for Upper Urinary Tract Calculi
- •Questions
- •Answers
- •55: Lower Urinary Tract Calculi
- •Questions
- •Answers
- •56: Benign Renal Tumors
- •Questions
- •Answers
- •57: Malignant Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •59: Retroperitoneal Tumors
- •Questions
- •Answers
- •60: Open Surgery of the Kidney
- •Questions
- •Answers
- •Questions
- •Answers
- •62: Nonsurgical Focal Therapy for Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •66: Surgery of the Adrenal Glands
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •71: Evaluation and Management of Women with Urinary Incontinence and Pelvic Prolapse
- •Questions
- •Answers
- •72: Evaluation and Management of Men with Urinary Incontinence
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •76: Overactive Bladder
- •Questions
- •Answers
- •77: Underactive Detrusor
- •Questions
- •Answers
- •78: Nocturia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •82: Retropubic Suspension Surgery for Incontinence in Women
- •Questions
- •Answers
- •83: Vaginal and Abdominal Reconstructive Surgery for Pelvic Organ Prolapse
- •Questions
- •Answers
- •Questions
- •Answers
- •85: Complications Related to the Use of Mesh and Their Repair
- •Questions
- •Answers
- •86: Injection Therapy for Urinary Incontinence
- •Questions
- •Answers
- •87: Additional Therapies for Storage and Emptying Failure
- •Questions
- •Answers
- •88: Aging and Geriatric Urology
- •Questions
- •Answers
- •89: Urinary Tract Fistulae
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •92: Tumors of the Bladder
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •95: Transurethral and Open Surgery for Bladder Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •99: Orthotopic Urinary Diversion
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Answers
- •Questions
- •Answers
- •108: Prostate Cancer Tumor Markers
- •Questions
- •Answers
- •Questions
- •110: Pathology of Prostatic Neoplasia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •114: Open Radical Prostatectomy
- •Questions
- •Answers
- •Questions
- •Answers
- •116: Radiation Therapy for Prostate Cancer
- •Questions
- •Answers
- •117: Focal Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •119: Management of Biomedical Recurrence Following Definitive Therapy for Prostate Cancer
- •Questions
- •Answers
- •120: Hormone Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •124: Perinatal Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •126: Pediatric Urogenital Imaging
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •133: Surgery of the Ureter in Children
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •137: Vesicoureteral Reflux
- •Questions
- •Answers
- •138: Bladder Anomalies in Children
- •Questions
- •Answers
- •139: Exstrophy-Epispadias Complex
- •Questions
- •Answers
- •140: Prune-Belly Syndrome
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •144: Management of Defecation Disorders
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •147: Hypospadias
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •152: Adolescent and Transitional Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •154: Pediatric Genitourinary Trauma
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
53
Strategies for Nonmedical Management of Upper Urinary Tract Calculi
Brian R. Matlaga; James E. Lingeman
Questions
1.The best predictor of post–percutaneous nephrolithotomy (PNL) urosepsis is:
a.preoperative bladder urine culture.
b.intraoperative bladder urine culture.
c.stone culture.
d.preoperative blood culture.
e.intraoperative blood culture.
2.What is the risk of mortality from an untreated struvite staghorn stone?
a.Less than 10%
b.10% to 30%
c.30% to 50%
d.50% to 70%
e.Greater than 70%
3.The increased risk of residual fragments after extracorporeal shockwave lithotripsy (SWL) of large-volume calculi is of particular importance for patients with stones composed of:
a.brushite.
b.uric acid.
c.struvite.
d.calcium oxalate monohydrate.
e.calcium oxalate dihydrate.
4.What is the single most important factor when choosing among SWL, ureteroscopic stone removal, and PNL for renal calculi?
a.Stone composition
b.Stone location
c.Anatomic abnormalities
d.Stone burden
e.Body habitus
5.What is the preferred treatment for a known brushite stone former harboring a lower pole renal calculus 25 mm in diameter?
a.SWL
b.SWL with ureteral stenting
c.Flexible ureteroscopy with holmium laser lithotripsy
d.PNL
e.Laparoscopic pyelolithotomy
6.What is the preferred initial treatment for staghorn calculi?
a.SWL with ureteral stenting
b.Flexible ureteroscopy with holmium laser lithotripsy
c.PNL
d.Extended pyelolithotomy
e.Anatrophic nephrolithotomy
7.Which of the following is the most difficult stone composition to fragment with SWL?
a.Calcium oxalate dihydrate
b.Calcium oxalate monohydrate
c.Struvite
d.Hydroxyapatite
e.Uric acid
8.What is the preferred treatment approach for a symptomatic 1.5-cm stone in a lower pole calyceal diverticulum?
a.SWL
b.Flexible ureteroscopy
c.PNL
d.PNL with fulguration of the diverticulum
e.Laparoscopic diverticulectomy
9.What is the preferred initial treatment for a 10-mm stone in the renal pelvis of a horseshoe kidney with minimal hydronephrosis?
a.SWL
b.Flexible ureteroscopy
c.PNL
d.Laparoscopic pyelolithotomy
e.Symphysiotomy with pyelolithotomy
.What is the preferred treatment approach for a 10-mm renal calculus in a patient who weighs 375 lb?
a.SWL
b.Flexible ureteroscopy
c.PNL
d.SWL using the "blast path" technique
e.Open surgery
.What is the preferred treatment option for a patient with a symptomatic 1.5-cm renal calculus and a coagulopathy?
a.SWL
b.SWL after administration of fresh-frozen plasma
c.Indwelling ureteral stent
d.Flexible ureteroscopy
e.PNL
.Residual fragments after SWL have been associated with which of the following?
a.Hypertension
b.An increased rate of recurrent stones
c.A decreased rate of recurrent stones
d.Perinephric hematomas
e.Hematuria
.What is the most sensitive test for identifying residual fragments after PNL?
a.Nephrotomography
b.Magnetic resonance imaging (MRI)
c.Ultrasonography
d.Noncontrast computed tomography (CT)
e.Contrast-enhanced CT
.Factors affecting the probability of spontaneous passage of ureteral calculi include all of the following EXCEPT:
a.stone size.
b.stone location at presentation.
c.stone composition.
d.degree of hydronephrosis.
e.duration of symptoms.
. Irreversible loss of renal function can occur within what time period when a
completely obstructing ureteral stone is present?
a.1 week
b.2 to 4 weeks
c.4 to 6 weeks
d.More than 6 weeks
e.3 months
.A first-time stone former is diagnosed with a 4-mm proximal ureteral calculus. The best initial management is:
a.ureteroscopic laser lithotripsy.
b.ureteral stent placement.
c.SWL.
d.expectant management.
e.SWL with ureteral stent placement.
.Large-volume matrix calculi, which form as a consequence of urinary tract infection, are:
a.effectively fragmented with SWL.
b.best approached in a ureteroscopic fashion.
c.generally sterile.
d.radiopaque and well visualized on plain radiographic studies.
e.most efficiently treated with PNL.
.Ureteral stent placement when SWL is performed for ureteral stones is appropriate for all of the following reasons EXCEPT:
a.solitary kidney.
b.relief of severe symptoms.
c.enhancement of stone fragmentation.
d.relief of obstruction.
e.aid in localization of difficult-to-visualize stones.
.The preferred single agent for medical expulsive therapy for distal ureteral calculi is:
a.nifedipine.
b.tamsulosin.
c.Solu-Medrol.
d.ibuprofen.
e.terazosin.
.The treatment modality associated with the greatest stone-free rates and the least morbidity for patients with distal ureteral stones of any size is:
a. PNL.